Today's Low
₹ 329.30
Today's High
₹ 342.15
52 Weeks Low
₹ 145.80
52 Weeks High
₹ 265.00
Lower
₹ 263.80
Upper
₹ 395.60
Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizers, hormones, iron supplements, neurology, oncology, pain management, respiratory, skin care, stress reliever, urology, vitamins/minerals/nutrients, and wound management. Venus Remedies Limited was incorporated in 1989 and is based in Panchkula, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 323.0 | 278.0 | 234.0 | 294.0 | 265.4 | 260.3 | 259.4 | 277.1 | 233.2 | 272.1 | 225.6 | 169.6 |
Total Non-Current Assets | 278.1 | 301.1 | 321.8 | 349.8 | 467.4 | 490.5 | 505.6 | 565.8 | 607.9 | 562.2 | 492.0 | 404.4 |
Total Assets | 601.1 | 579.1 | 555.9 | 643.8 | 732.8 | 750.8 | 765.0 | 842.8 | 841.1 | 834.4 | 717.6 | 574.0 |
Total Current Liabilities | 82.6 | 92.7 | 97.5 | 224.6 | 263.6 | 230.4 | 196.8 | 193.1 | 162.8 | 211.0 | 191.3 | 153.2 |
Total Non-Current Liabilities | 58.2 | 46.0 | 58.1 | 95.8 | 136.7 | 158.5 | 179.5 | 212.1 | 221.6 | 161.8 | 147.2 | 113.5 |
Shareholder's Funds | 460.3 | 440.5 | 400.3 | 323.4 | 332.5 | 361.9 | 388.7 | 437.6 | 456.7 | 461.6 | 379.1 | 307.3 |
Total Liabilities | 601.1 | 579.1 | 555.9 | 643.8 | 732.8 | 750.8 | 765.0 | 842.8 | 841.1 | 834.4 | 717.6 | 574.0 |
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of 0.68, which results in a Negative aspect.
The Industry Price to BV stands at 6.03, vs the Price to BV of 0.92, which results in a Negative aspect.
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 0.68, which results in a Negative aspect.
The Industry Current Ratio stands at 2.31, vs the Current Ratio of 1.31, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 555.5 | 600.2 | 548.1 | 339.3 | 321.9 | 372.4 | 400.0 | 418.3 | 464.0 | 541.6 | 468.6 | 409.8 |
Total Expenditure | 495.3 | 538.1 | 494.4 | 298.5 | 289.4 | 332.9 | 349.3 | 337.1 | 374.8 | 403.3 | 348.5 | 307.0 |
Operating Profit(Excl OI) | 70.5 | 70.4 | 73.4 | 46.1 | 38.6 | 41.9 | 55.0 | 83.2 | 89.9 | 138.7 | 120.5 | 103.4 |
Add: Other Income | 10.3 | 8.3 | 19.6 | 5.3 | 6.1 | 2.4 | 4.3 | 2.0 | 0.7 | 0.5 | 0.4 | 0.5 |
Operating Profit | 70.5 | 70.4 | 73.4 | 46.1 | 38.6 | 41.9 | 55.0 | 83.2 | 89.9 | 138.7 | 120.5 | 103.4 |
Less: Interest | 0.3 | 0.5 | 13.0 | 13.3 | 25.4 | 35.6 | 36.4 | 38.0 | 41.2 | 29.4 | 24.6 | 27.5 |
PBDT | 70.2 | 69.9 | 60.4 | 32.8 | 13.2 | 6.3 | 18.6 | 45.2 | 48.6 | 109.3 | 95.9 | 75.9 |
Less: Depreciation Amortization | 32.3 | 33.5 | 35.3 | 32.0 | 34.0 | 33.8 | 40.3 | 41.7 | 46.0 | 40.2 | 33.1 | 25.0 |
PBT & Exceptional Items | 37.9 | 36.4 | 25.1 | 0.8 | -20.8 | -27.5 | -21.6 | 3.5 | 2.7 | 69.1 | 62.8 | 50.9 |
Less: Exceptional Income Expenses | 0.0 | 0.0 | 23.4 | -8.8 | -9.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit Before Tax | 37.9 | 36.4 | 48.6 | -8.0 | -29.7 | -27.5 | -21.6 | 3.5 | 2.7 | 69.1 | 62.8 | 50.9 |
Less: Taxation | 11.4 | -4.3 | -13.2 | 2.0 | -1.2 | 3.2 | -4.6 | 1.8 | -2.5 | 4.8 | 5.5 | 3.8 |
Profit After Tax | 26.6 | 40.7 | 61.8 | -10.0 | -28.6 | -30.7 | -17.1 | 1.7 | 5.2 | 64.3 | 57.3 | 47.1 |
Earnings Per Share | 0.2 | 0.3 | 0.5 | -0.1 | -0.2 | -0.3 | -0.1 | 0.0 | 0.1 | 0.6 | 0.5 | 0.5 |
The Industry Dividend Yield stands at 0.60, vs the Dividend Yield of 0.00, which results in a Negative aspect.
The Industry PAT Margin stands at 9.77, vs the PAT Margin of -2.95, which results in a Negative aspect.
The Industry PAT Growth stands at 32.18, vs the PAT Growth of 65.01, which results in a Positive aspect.
The Industry PE Ratio stands at 42.56, vs the PE Ratio of 15.15, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | 37.9 | 36.4 | 25.1 | 0.8 | -20.8 | -27.5 | -21.6 | 3.5 | 2.6 | 69.1 | 62.8 | 50.9 |
Tax Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Adjustment | 23.3 | 26.3 | 21.9 | 41.6 | 60.7 | 66.2 | 70.6 | 56.4 | 83.6 | 37.2 | 40.7 | 30.0 |
Changes In Working Capital | 37.9 | 36.4 | 25.1 | 0.8 | -20.8 | -27.5 | -21.6 | 3.5 | 2.6 | 69.1 | 62.8 | 50.9 |
Cash Flow after changes in Working Capital | 36.6 | 41.1 | 108.4 | 63.2 | 45.3 | 31.2 | 58.9 | 46.9 | 67.8 | 52.6 | 52.2 | 41.7 |
Cash Flow from Operating Activities | 36.6 | 41.1 | 131.8 | 77.6 | 45.3 | 31.2 | 58.9 | 46.9 | 67.8 | 52.6 | 52.2 | 41.7 |
Cash Flow from Investing Activities | -50.8 | -16.7 | 56.5 | -4.7 | -11.3 | -11.5 | -18.3 | 2.9 | -67.2 | -94.7 | -103.9 | -95.2 |
Cash Flow from Financing Activities | -0.6 | -9.5 | -162.2 | -73.0 | -35.2 | -39.2 | -44.1 | -46.3 | -1.4 | 40.1 | 55.2 | 53.3 |
Net Cash Inflow / Outflow | -14.8 | 14.9 | 26.1 | -0.1 | -1.2 | -19.5 | -3.5 | 3.5 | -0.8 | -2.0 | 3.4 | -0.2 |
Opening Cash & Cash Equivalents | 43.3 | 28.9 | 1.9 | 2.0 | 4.0 | 0.0 | 7.1 | 3.6 | 4.4 | 6.4 | 2.9 | 3.1 |
Closing Cash & Cash Equivalent | 21.2 | 43.3 | 28.9 | 1.9 | 2.8 | -19.5 | 3.6 | 7.1 | 3.6 | 4.4 | 6.4 | 3.0 |
The Industry PFCF Ratio stands at 25.12, vs the PFCF Ratio of 0.79, which results in a Negative aspect.
The Industry PCF RATIO stands at 24.29, vs the PCF RATIO of 0.36, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 1,434.2 | 1,677.2 | 951.5 | 1,556.4 | 1,169.0 | 1,398.9 | 1,430.8 | 1,419.4 | 1,243.4 | 2,025.6 | 1,298.1 | 1,113.7 | 1,219.4 | 1,260.7 | 1,887.5 | 830.6 |
Total Income | 1,457.7 | 1,707.7 | 974.1 | 1,590.5 | 1,207.1 | 1,416.8 | 1,445.2 | 1,441.8 | 1,255.6 | 2,054.5 | 1,317.7 | 1,148.6 | 1,237.7 | 1,383.5 | 1,907.8 | 862.5 |
Total Expenditure | 1,313.8 | 1,499.3 | 847.5 | 1,310.3 | 1,088.0 | 1,269.2 | 1,285.7 | 1,363.9 | 1,119.1 | 1,752.6 | 1,129.8 | 1,068.8 | 1,038.6 | 1,154.2 | 1,731.9 | 755.3 |
PBIDT (Excl OI) | 120.4 | 177.9 | 104.0 | 246.1 | 81.0 | 129.7 | 145.1 | 55.4 | 124.4 | 273.0 | 168.3 | 45.0 | 180.8 | 106.5 | 155.5 | 75.4 |
Other Income | 23.5 | 30.5 | 22.6 | 34.1 | 38.1 | 17.9 | 14.4 | 22.5 | 12.2 | 28.9 | 19.5 | 34.9 | 18.3 | 122.8 | 20.4 | 31.8 |
Operating Profit | 143.9 | 208.4 | 126.6 | 280.2 | 119.1 | 147.6 | 159.5 | 77.9 | 136.5 | 301.9 | 187.8 | 79.9 | 199.1 | 229.2 | 175.9 | 107.2 |
Interest | 0.7 | 0.6 | 0.6 | 0.0 | 1.5 | 0.0 | 2.6 | 0.0 | 3.1 | 0.3 | 1.4 | 9.6 | 18.1 | 73.9 | 28.5 | 0.0 |
Exceptional Items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 205.5 | 44.6 | 75.9 | -91.7 | -88.1 |
PBDT | 143.2 | 207.8 | 126.0 | 280.2 | 117.6 | 147.6 | 156.9 | 77.9 | 133.4 | 301.7 | 186.4 | 275.8 | 225.6 | 231.3 | 55.6 | 19.1 |
Depreciation | 65.4 | 64.4 | 75.5 | 82.9 | 72.2 | 89.9 | 78.0 | 75.6 | 86.4 | 87.1 | 86.2 | 93.8 | 87.0 | 86.1 | 35.9 | 64.7 |
Profit Before Tax | 77.8 | 143.4 | 50.5 | 197.3 | 45.4 | 57.7 | 78.9 | 2.3 | 47.0 | 214.6 | 100.2 | 182.0 | 138.6 | 145.2 | 19.7 | -45.7 |
Tax | 9.3 | 44.0 | 38.7 | 86.7 | 12.5 | 4.4 | 10.0 | 0.0 | -9.5 | -16.9 | -16.8 | -169.1 | 22.1 | 14.9 | 0.0 | 8.2 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 68.5 | 99.4 | 11.8 | 110.6 | 32.9 | 53.3 | 68.9 | 2.3 | 56.5 | 231.5 | 117.0 | 351.1 | 116.6 | 130.3 | 19.7 | -53.8 |
Net Profit | 68.5 | 99.4 | 11.8 | 110.6 | 32.9 | 53.3 | 68.9 | 2.3 | 56.5 | 231.5 | 117.0 | 351.1 | 116.6 | 130.3 | 19.7 | -53.8 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 133.7 | 133.7 | 133.7 | 133.7 | 133.7 | 133.7 | 133.7 | 133.7 | 133.7 | 133.7 | 133.7 | 123.4 | 123.4 | 123.4 | 123.4 | 123.4 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 5.1 | 7.4 | 0.9 | 8.3 | 2.5 | 4.0 | 5.2 | 0.2 | 4.2 | 17.3 | 8.9 | 28.5 | 9.4 | 10.6 | 1.6 | -4.4 |
Operating Profit Margin | 10.0 | 12.4 | 13.3 | 18.0 | 10.2 | 10.6 | 11.1 | 5.5 | 11.0 | 14.9 | 14.5 | 7.2 | 16.3 | 18.2 | 9.3 | 12.9 |
Net Profit Margin | 4.8 | 5.9 | 1.2 | 7.1 | 2.8 | 3.8 | 4.8 | 0.2 | 4.5 | 11.4 | 9.0 | 31.5 | 9.6 | 10.3 | 1.0 | -6.5 |
The Industry Net Sales Growth stands at 11.07, vs the Net Sales Growth of 5.42, which results in a Negative aspect.
The Industry Mcap Growth stands at 19.69, vs the Mcap Growth of -32.13, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 368.50 | 390.55 | 339.65 |
R3 | 359.98 | 358.55 | 334.17 |
R2 | 351.47 | 350.75 | 332.35 |
R1 | 340.08 | 338.65 | 330.52 |
Pivot | 331.57 | 330.85 | 331.57 |
S1 | 320.18 | 318.75 | 326.88 |
S2 | 311.67 | 310.95 | 325.05 |
S3 | 300.28 | 298.85 | 323.23 |
S4 | 288.90 | 271.15 | 317.76 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
56.50
Neutral
RSI
47.41
Neutral
ROC
-3.74
Bearish
UltimateOscillator
44.77
Neutral
Williams Indicator
-47.88
Neutral
CCI Indicator
18.38
Neutral
MACD
-2,673.52
Bearish
Stochastic Indicator
53.94
Neutral
ATR
16.06
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|
Date Of Conduct | Board Meeting Details |
---|---|
14-02-2024 | Quarterly Results |
09-11-2023 | Quarterly Results |
14-08-2023 | Quarterly Results |
14-07-2023 | VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/07/2023 ,inter alia, to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on 14th July 2023 inter alia: 1. To consider the appointment of Statutory Auditor of the Company. 2. To finalize the date of 34th Annual General Meeting of the company. 3. Any other business with permission of the Chair. |
29-05-2023 | Audited Results |
30-01-2023 | Quarterly Results |
12-11-2022 | Quarterly Results |
30-07-2022 | Quarterly Results |
27-05-2022 | Audited Results |
31-01-2022 | Quarterly Results |
30-12-2021 | Inter alia, to consider the appointment of additional director Independent director. |
30-10-2021 | Quarterly Results |
12-08-2021 | Quarterly Results & A.G.M. |
31-05-2021 | Preferential Issue of shares & Audited Results |